Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
06/20/2023

AGEPHA Pharma Media

AGEPHA Pharma Media
Following a Priority Review, the U.S. FDA has approved LODOCO® as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and...
Following a Priority Review, the U.S. FDA has approved LODOCO® as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and...
Following a Priority Review, the...
06/20/2023
Cath Lab Digest
TAVR CENTER NEWS
MultiCare’s Pulse Heart Institute (PHI), in Partnership With Tacoma General Hospital, Successfully Implants 1000th Transcatheter Aortic Valve
06/20/2023

Pulse Heart Institute News

Pulse Heart Institute News
PHI is the first program in the South Sound region of Western Washington to achieve this milestone and continues to lead as the largest transcatheter aortic valve program in the region.
PHI is the first program in the South Sound region of Western Washington to achieve this milestone and continues to lead as the largest transcatheter aortic valve program in the region.
PHI is the first program in the...
06/20/2023
Cath Lab Digest

Advertisement

News
Dialysis Vascular Access Coalition (DVAC) Supports New Legislation to Stop Ongoing Cuts to Office-Based Specialists
06/15/2023
WASHINGTON, DC — Today, the Dialysis Vascular Access Coalition (DVAC) publicly supported the Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674), introduced by Rep. Gus Bilirakis (R-FL-12), Rep. Tony Cardenas...
WASHINGTON, DC — Today, the Dialysis Vascular Access Coalition (DVAC) publicly supported the Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674), introduced by Rep. Gus Bilirakis (R-FL-12), Rep. Tony Cardenas...
WASHINGTON, DC — Today, the...
06/15/2023
Cath Lab Digest
News
NEJM: Transthyretin (ATTR) Amyloidosis, a Devastating Heart Condition, Can Be Reversed, Study Shows for First Time
06/14/2023
The new study, published as a letter in The New England Journal of Medicine, reports on three men, aged 68, 76 and 82, who were diagnosed with transthyretin cardiac amyloidosis but who later recovered.
The new study, published as a letter in The New England Journal of Medicine, reports on three men, aged 68, 76 and 82, who were diagnosed with transthyretin cardiac amyloidosis but who later recovered.
The new study, published as a...
06/14/2023
Cath Lab Digest
News
Study: Black Patients Nearly 50% Less Likely Than White Patients to Receive Vascular Interventions That Could Potentially Avoid Adverse Outcomes
06/14/2023
The study discovered that Black patients are more likely to only receive medication and lifestyle change recommendations, while white patients also receive revascularization.
The study discovered that Black patients are more likely to only receive medication and lifestyle change recommendations, while white patients also receive revascularization.
The study discovered that Black...
06/14/2023
Cath Lab Digest

Advertisement

News
Philips' Direct-to-Angio Stroke Pathway: New Analysis Demonstrates Substantial Cost Savings in Addition to Improved Patient Outcomes
06/14/2023
The retrospective analysis looked at data from the controlled single-center ANGIOCAT clinical trial conducted at the Vall d’Hebron University Hospital Stroke Unit (Barcelona, Spain) [1]. Earlier results from this study demonstrated that a...
The retrospective analysis looked at data from the controlled single-center ANGIOCAT clinical trial conducted at the Vall d’Hebron University Hospital Stroke Unit (Barcelona, Spain) [1]. Earlier results from this study demonstrated that a...
The retrospective analysis...
06/14/2023
Cath Lab Digest
News
DEEPER OUS Trial Evaluating Reflow Medical’s Bare Temporary Spur Stent System Shows Positive Results at 6 Months
06/12/2023
SAN CLEMENTE, Calif. -- June 12, 2023 -- Reflow Medical, Inc. announced the 6-month results of the DEEPER OUS clinical trial (NCT03807531) evaluating the safety and efficacy of the Bare Temporary Spur Stent System. Results were presented at...
SAN CLEMENTE, Calif. -- June 12, 2023 -- Reflow Medical, Inc. announced the 6-month results of the DEEPER OUS clinical trial (NCT03807531) evaluating the safety and efficacy of the Bare Temporary Spur Stent System. Results were presented at...
SAN CLEMENTE, Calif. -- June 12,...
06/12/2023
Vascular Disease Management
News
FDA Approves Bipolar Temporary Pacing Guidewire Designed Specifically for Use During TAVR and Balloon Aortic Valvuloplasty 
06/08/2023
Teleflex announced it will feature the Wattson® Temporary Pacing Guidewire — a bipolar temporary pacing guidewire designed specifically for use during TAVR and balloon aortic valvuloplasty – at TVT: The Structural Heart Summit.
Teleflex announced it will feature the Wattson® Temporary Pacing Guidewire — a bipolar temporary pacing guidewire designed specifically for use during TAVR and balloon aortic valvuloplasty – at TVT: The Structural Heart Summit.
Teleflex announced it will...
06/08/2023
Cath Lab Digest

Advertisement

News
DASI Simulation’s Precision TAVI earns FDA Clearance
06/08/2023
DUBLIN, OHIO, USA -- DASI Simulations announced it has received FDA clearance for its first product - Precision TAVI. DASI aims to bring advanced, artificial intelligence (AI)-driven individualized computer predictive modeling for improved...
DUBLIN, OHIO, USA -- DASI Simulations announced it has received FDA clearance for its first product - Precision TAVI. DASI aims to bring advanced, artificial intelligence (AI)-driven individualized computer predictive modeling for improved...
DUBLIN, OHIO, USA -- DASI...
06/08/2023
Cath Lab Digest
News
Endologix Receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD
06/08/2023
June 08, 2023 – IRVINE, Calif – Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the U.S. Food and Drug...
June 08, 2023 – IRVINE, Calif – Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the U.S. Food and Drug...
June 08, 2023 – IRVINE,...
06/08/2023
Vascular Disease Management

Advertisement

Advertisement

Subscriber

Cath Lab Digest Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use